Welcome to our dedicated page for bioAffinity Technologies SEC filings (Ticker: BIAFW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on bioAffinity Technologies's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into bioAffinity Technologies's regulatory disclosures and financial reporting.
bioAffinity Technologies, Inc. disclosed that Nasdaq notified the company it failed to maintain the $1.00 minimum bid price for the period December 23, 2024 through February 6, 2025 and did not regain compliance by the 180-day cure deadline. The Listing Qualifications Staff also determined the company is ineligible for a second compliance period because its reported stockholders' equity of $1,439,404 as of March 31, 2025 is below Nasdaq's $2,500,000 minimum for continued listing.
The company was told its securities will be scheduled for delisting and suspended at the opening of business on August 18, 2025 unless it requests an appeal by August 14, 2025. bioAffinity intends to file an appeal to stay the suspension and will present its plan to regain compliance; hearings are typically scheduled ~30-45 days after a hearing request and the Panel typically issues a decision within ~30 days after the hearing. The filing also notes a press release announcing increased commercial sales of CyPath® Lung.
bioAffinity Technologies, Inc. (symbol BIAFW) has submitted a post-effective amendment on Form POS AM. The excerpt provided is almost entirely made up of XBRL tag references that map the company’s equity classes, incentive plans, warrants and other membership interests across various reporting periods. No narrative discussion, transaction description, or quantitative financial statements accompany the tags. As presented, the amendment appears to be an administrative update to existing registration statements—likely refreshing or re-labeling warrant-related securities—rather than announcing new capital raises or operational developments.
Because the filing lacks earnings data, cash-flow details, or material corporate actions, it offers no immediate insight into profitability, liquidity, or strategy. For investors, the document’s impact is therefore minimal unless later supplemented by a prospectus or pricing information that changes dilution expectations.
bioAffinity Technologies has filed a POS AM (Post-Effective Amendment) related to their warrant securities (BIAFW). The filing includes several key warrant-related developments:
- Multiple Warrant Offerings: The company has various warrant classes including tradeable and non-tradeable warrants, pre-IPO convertible notes, and placement agent warrants
- Recent Warrant Activity: Notable warrant transactions occurred in March 2024, August 2024, and October 2024, with additional warrant inducement events in February 2025
- Equity Incentive Plans: The company maintains both 2014 and 2024 equity incentive plans, including restricted stock units (RSUs) and stock options for employees, non-employees, and board members
- Financial Structure: The filing details the company's capital structure including common stock, preferred stock, and various warrant classifications with their respective terms and conditions
This amendment appears to update and clarify the terms and conditions of the company's outstanding warrants and related securities, ensuring compliance with SEC regulations and providing updated information to investors.